Business Wire

Recordati Rare Diseases: Positive Results From the Phase III LINC 4 Study Presented Today at the Endocrine Society’s Annual Meeting Reinforce the Efficacy and Safety of ...

PUTEAUX, France--(BUSINESS WIRE)--Recordati Rare Diseases announces that positive results from the Phase III LINC 4 study of Isturisa® were presented on March 22 at The Endocrine Society’s Annual ...
Business Wire

Recordati Rare Diseases Announce Publication of Long-term Outcomes From the Extension to the Phase III LINC 3 Study of Isturisa® (Osilodrostat) in Patients With Cushing’s ...

PUTEAUX, France--(BUSINESS WIRE)--Recordati Rare Diseases announce today publication of the long-term outcomes from the open-label extension period of the Phase III LINC 3 study of Isturisa® in The ...
Nasdaq

Corcept (CORT) Rises as Cushing's Syndrome Study Meets Goal

Corcept Therapeutics Incorporated CORT announced that the pivotal phase III GRACE study, which evaluated its lead pipeline candidate, relacorilant, for treating patients with Cushing’s syndrome, met ...
FierceBiotech

Corcept Therapeutics Inc. (CORT) Announces Key Secondary Endpoint Was Met in Phase 3 Study of Corlux for Cushing's Syndrome

(Marketwire - January 11, 2011) - Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced positive results on the key secondary endpoint of "global clinical improvement" in its Phase 3 study ...
FierceBiotech

Corcept Therapeutics Announces Positive Phase 3 Study Results for CORLUX for the Treatment of Cushing's Syndrome

Corcept Therapeutics Incorporated ("Corcept") (NASDAQ: CORT) today announced positive top-line results from its Phase 3 study of CORLUX for the treatment of Cushing's Syndrome. The study evaluated the ...